In June 2024, COFEPRIS warned about the risks of using semaglutide and liraglutide without medical supervision. These medications, used for diabetes and weight management, can cause adverse effects, including nausea, kidney damage, and mental health …

The outcome could be a price-crushing free-for-all or a more measured market shaped by court rulings and innovative challengers. Novo’s U.S. price cut shows how global dynamics may spill into China, reinforcing that survival will …